Management of Pain Associated With Failed Back Surgery Syndrome
Primary Purpose
Failed Back Surgery Syndrome
Status
Completed
Phase
Phase 4
Locations
Iraq
Study Type
Interventional
Intervention
Pregabalin 75mg
Gabapentin 300mg
Sponsored by
About this trial
This is an interventional treatment trial for Failed Back Surgery Syndrome focused on measuring Pregabalin, Gabapentin, neuropathic pain, spine surgery
Eligibility Criteria
Inclusion Criteria:
- Patients with Previous spine surgery and subsequent chronic back pain
Exclusion Criteria:
- Patients with connective tissue diseases
- Patients with psychiatric illnesses
Sites / Locations
- Laith Thamer Al-Ameri
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Pregabalin
Gabapentin
Arm Description
A dose of 75 mg of Pregabalin twice daily for one month will be prescribed to each patient enrolled this study arm
A dose of 300 mg of Gabapentin twice daily for one month will be prescribed to each patient enrolled this study arm
Outcomes
Primary Outcome Measures
Efficacy in Neuropathic pain management
Visual analogue scale pain, minimum score is 0, maximum is 10, the higher ther score the more severe pain
Secondary Outcome Measures
Full Information
NCT ID
NCT05324761
First Posted
March 20, 2022
Last Updated
April 28, 2023
Sponsor
Al-Kindy College of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT05324761
Brief Title
Management of Pain Associated With Failed Back Surgery Syndrome
Official Title
Pregabalin Versus Gabapentin Efficacy in the Management of Neuropathic Pain Associated With Failed Back Surgery Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
April 25, 2022 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
June 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Al-Kindy College of Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Neuropathic pain is a common complication following different types of spine surgery making negative impact on health, along with life style changes and management, many neurologist prescribed either Pregabalin or Gabapentin to manage this condition with overall good results.
our study aims to evaluate the efficacy of Pregabalin and Gabapentin in the management of this condition and to compare between them
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Failed Back Surgery Syndrome
Keywords
Pregabalin, Gabapentin, neuropathic pain, spine surgery
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pregabalin
Arm Type
Active Comparator
Arm Description
A dose of 75 mg of Pregabalin twice daily for one month will be prescribed to each patient enrolled this study arm
Arm Title
Gabapentin
Arm Type
Active Comparator
Arm Description
A dose of 300 mg of Gabapentin twice daily for one month will be prescribed to each patient enrolled this study arm
Intervention Type
Drug
Intervention Name(s)
Pregabalin 75mg
Intervention Description
Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
Intervention Type
Drug
Intervention Name(s)
Gabapentin 300mg
Intervention Description
Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
Primary Outcome Measure Information:
Title
Efficacy in Neuropathic pain management
Description
Visual analogue scale pain, minimum score is 0, maximum is 10, the higher ther score the more severe pain
Time Frame
outcome will be assessed one month after the initiation of medication
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with Previous spine surgery and subsequent chronic back pain
Exclusion Criteria:
Patients with connective tissue diseases
Patients with psychiatric illnesses
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laith Al-Ameri
Organizational Affiliation
University of Baghdad - Al-Kindy College of Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Laith Thamer Al-Ameri
City
Baghdad
Country
Iraq
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Management of Pain Associated With Failed Back Surgery Syndrome
We'll reach out to this number within 24 hrs